Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemigliptin add-on therapy in type 2 diabetes inadequately controlled on metformin + SGLT2 inhibitor
KCT0010445Phase 4Recruiting
- Sponsor
- LG Chem
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of gemigliptin in type 2 diabetes mellitus (T2DM), sponsored by LG Chem. Started Sep 2025; status: recruiting.
02
Drugs
gemigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on KCT0010445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010445.